Samsara BioCapital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Samsara BioCapital’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,669	Closed	-$55.8K	–	55
2023 Q1	$55.8K	Hold	13,669	–	–	0.01%	54
2022 Q4	$68.6K	Hold	13,669	–	–	0.01%	53
2022 Q3	$179K	Hold	13,669	–	–	0.04%	53
2022 Q2	$175K	Hold	13,669	–	–	0.05%	54
2022 Q1	$208K	Hold	13,669	–	–	0.05%	55
2021 Q4	$242K	Hold	13,669	–	–	0.05%	49
2021 Q3	$287K	Sell	13,669 -4,556	-25%	-$100K	0.05%	46
2021 Q2	$359K	Hold	18,225	–	–	0.04%	48
2021 Q1	$530K	Hold	18,225	–	–	0.1%	42
2020 Q4	$552	Sell	18,225 -18,226	-50%	-$399K	0.06%	42
2020 Q3	$580K	Sell	36,451 -12,151	-25%	-$222K	0.16%	35
2020 Q2	$959K	Buy	+48,602	New	+$929K	0.31%	28

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Samsara BioCapital's NGM Position: Q2 2023 in Review

Samsara BioCapital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 13,669 shares — an estimated $55.8K sold.

Samsara BioCapital first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $959K in Q2 2020. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Samsara BioCapital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Samsara BioCapital sold 13,669 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $55.8K.
Samsara BioCapital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
Samsara BioCapital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $959K in Q2 2020.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.